Edmond DE Rothschild Holding S.A. Cuts Stake in Moderna, Inc. (NASDAQ:MRNA)

Edmond DE Rothschild Holding S.A. lowered its stake in Moderna, Inc. (NASDAQ:MRNA) by 22.8% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 74,083 shares of the company’s stock after selling 21,888 shares during the quarter. Edmond DE Rothschild Holding S.A.’s holdings in Moderna were worth $3,080,000 as of its most recent filing with the SEC.

Other hedge funds have also modified their holdings of the company. Cerity Partners LLC raised its stake in shares of Moderna by 7.0% during the third quarter. Cerity Partners LLC now owns 13,769 shares of the company’s stock valued at $920,000 after purchasing an additional 900 shares during the period. Quantbot Technologies LP purchased a new stake in Moderna during the 3rd quarter worth $150,000. Townsquare Capital LLC lifted its holdings in Moderna by 42.7% in the 3rd quarter. Townsquare Capital LLC now owns 5,288 shares of the company’s stock worth $353,000 after buying an additional 1,583 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Moderna by 17.6% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 157,774 shares of the company’s stock valued at $10,544,000 after buying an additional 23,631 shares during the last quarter. Finally, Public Sector Pension Investment Board grew its stake in shares of Moderna by 18.0% during the third quarter. Public Sector Pension Investment Board now owns 16,380 shares of the company’s stock valued at $1,095,000 after acquiring an additional 2,500 shares in the last quarter. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Moderna Trading Down 8.9 %

Shares of NASDAQ:MRNA opened at $28.35 on Tuesday. The firm’s 50 day moving average is $34.60 and its two-hundred day moving average is $43.84. The firm has a market capitalization of $10.96 billion, a P/E ratio of -3.05 and a beta of 1.86. Moderna, Inc. has a 52 week low of $26.80 and a 52 week high of $170.47.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. Berenberg Bank increased their price target on Moderna from $33.00 to $42.00 and gave the company a “hold” rating in a report on Thursday, January 16th. Evercore ISI set a $50.00 target price on Moderna in a research note on Friday, February 14th. Royal Bank of Canada restated a “sector perform” rating and issued a $40.00 price target on shares of Moderna in a research note on Tuesday, February 18th. Argus downgraded shares of Moderna from a “buy” rating to a “hold” rating in a research note on Wednesday, December 18th. Finally, Leerink Partners dropped their target price on shares of Moderna from $31.00 to $27.00 and set an “underweight” rating for the company in a research report on Thursday, January 16th. Four analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $59.00.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.